News

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Xenon in $646 million deal with Roche unit

10-01-2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

COMPANY SPOTLIGHT

Menarini

Back to top